The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Allemani, C., Weir, H. K., Carreira, H., Harewood, R., Spika, D., Wang, X.-S., Bannon, F., Ahn, J. V., Johnson, C. J., Bonaventure, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62038-9 · Cited by 2,614
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804710 · Cited by 2,397
Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoehn, J. L., Vogel, V. G., Dakhil, S. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0235 · Cited by 1,789
Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70257-6 · Cited by 1,674
Mustian, K. M., Alfano, C. M., Heckler, C., Kleckner, A. S., Kleckner, I. R., Leach, C. R., Mohr, D., Palesh, O. G., Peppone, L. J., Piper, B. F., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.6914 · Cited by 932
Research works printed but not linked: 22
- Association of Breast Surgery at Baso 2009, 2009, Surgical guidelines for the management of breast cancer. Eur J Surg Oncol, 35, 1
- Bentzen, 2008, The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial, Lancet, 371, 1098, 10.1016/S0140-6736(08)60348-7 · DOI · Paper page
- Blamey, 2007, Reading the prognosis of the individual with breast cancer, Eur J Cancer, 43, 1545, 10.1016/j.ejca.2007.01.003 · DOI
- Bundred, 2008, Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results, Cancer, 112, 1001, 10.1002/cncr.23259 · DOI · Paper page
- Coombes, 2007, Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial, Lancet, 369, 559, 10.1016/S0140-6736(07)60200-1 · DOI · Paper page
- Early Breast Cancer Trialists’ Collaborative Group, 2005, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet, 365, 1687, 10.1016/S0140-6736(05)66544-0 · DOI · Paper page
- EUSOMA, 2000, The requirements of a specialist breast unit, Eur J Cancer, 36, 2288, 10.1016/S0959-8049(00)00180-5 · doi:10.1016/s0959-8049(00)00180-5
- Gianni, 2009, Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer, J Clin Oncol, 27, 2474, 10.1200/JCO.2008.19.2567 · DOI · Paper page
- Gnant, 2009, Endocrine therapy plus zoledronic acid in premenopausal breast cancer, N Engl J Med, 360, 679, 10.1056/NEJMoa0806285 · DOI · Paper page
- Gnant, 2007, Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group, J Clin Oncol, 25, 820, 10.1200/JCO.2005.02.7102 · DOI · Paper page
- Goldhirsch, 2009, Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009, Ann Oncol, 20, 1319, 10.1093/annonc/mdp322 · DOI · Paper page
- Gondos, 2009, Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis, Ann Oncol, 20, 564, 10.1093/annonc/mdn639 · DOI
- Group, 2009, Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer, N Engl J Med, 361, 766, 10.1056/NEJMoa0810818 · DOI · Paper page
- Hershman, 2008, Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer, J Clin Oncol, 26, 4739, 10.1200/JCO.2008.16.4707 · DOI
- Hughes, 2004, Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer, N Engl J Med, 351, 971, 10.1056/NEJMoa040587 · DOI · Paper page
- Isern, 2008, Histopathological findings and follow-up after prophylactic mastectomy and immediate breast reconstruction in 100 women from families with hereditary breast cancer, Eur J Surg Oncol, 34, 1148, 10.1016/j.ejso.2008.03.002 · DOI
- Nicholson, 2007, A comparison of the cosmetic and psychological outcome of breast reconstruction, breast conserving surgery and mastectomy without reconstruction, Breast, 16, 396, 10.1016/j.breast.2007.01.009 · DOI
- Olivotto, 2005, Population-based validation of the prognostic model ADJUVANT! for early breast cancer, J Clin Oncol, 23, 2716, 10.1200/JCO.2005.06.178 · DOI · Paper page
- Reid, 2008, Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group, Cancer Treat Rev, 34, S3, 10.1016/j.ctrv.2008.03.007 · DOI
- Romond, 2005, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, N Engl J Med, 353, 1673, 10.1056/NEJMoa052122 · DOI · Paper page
- Viale, 2008, Comparative evaluation of an extensive histopathologic examination and a real-time reverse-transcription-polymerase chain reaction assay for mammaglobin and cytokeratin 19 on axillary sentinel lymph nodes of breast carcinoma patients, Ann Surg, 247, 136, 10.1097/SLA.0b013e318157d22b · doi:10.1097/sla.0b013e318157d22b
- Wolff, 2007, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, J Clin Oncol, 25, 118, 10.1200/JCO.2006.09.2775 · DOI · Paper page
Cited by
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Schmid, P., Rugo, H. S., Adams, S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Henschel, V., Molinero, L., Chui, S. Y., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30689-8 · Cited by 1,216
Mittendorf, E. A., Zhang, H., Barrios, C. H., Saji, S., Jung, K. H., Hegg, R., Koehler, A., Sohn, J., Iwata, H., Telli, M. L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31953-x · Cited by 1,083
Patel, H. K., & Bihani, T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.012 · Cited by 499
Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments
Gillespie, T. C., Sayegh, H. E., Brunelle, C. L., Daniell, K. M., & Taghian, A. G. (2018) · Gland Surgery · doi:10.21037/gs.2017.11.04 · Cited by 361
Metadata
- Authors
- Aebi, S., Davidson, T., Gruber, G., & Castiglione, M.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2010-05
- Volume
- 21
- Issue
- 10
- Pages
- v9-v14
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2128458647
- Cited by
- 2,842
- References
- 12
- FWCI
- 11.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 3524 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. https://app.cochat.ai/papers/10.1093/annonc/mdq159
- The paper
- Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010). Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. https://doi.org/10.1093/annonc/mdq159
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
